Cardiff Oncology (NASDAQ:CRDF) had its "buy" rating reaffirmed by analysts at HC Wainwright.
Cardiff Oncology, Inc. (CRDF) Discusses Management Transition and Onvansertib Phase II Data Update in RAS-Mutated mCRC Transcript [Seeking Alpha]
Cardiff Oncology Announces Positive Update from its Randomized Phase 2 Trial of Onvansertib in First-line RAS-mutated mCRC
Cardiff Oncology Announces Executive Leadership Changes as it Transitions to Late-Stage Clinical Development
Cardiff Oncology: What Storms Can We Expect In 2026? The Case For Measured Enthusiasm [Seeking Alpha]